EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Progress in the Vaccine Development Against Epstein–Barr Virus

Yihao Dai, Botian Zhang, Luming Yang, Shuo Tao, Yijing Yu, Conglei Li

Viruses · 30.06.2025 · 17 (7) · 936

DOI: 10.3390/v17070936 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 30.06.2025. Verfasst von Yihao Dai und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Epstein-Barr Virus Infections, Vaccine Development, Viral Vaccines. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Program (Conglei Li), Guangdong Basic and Applied Basic Research Foundation (Conglei Li), Shenzhen Medical Research Fund (Conglei Li).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Epstein–Barr virus (EBV) is the first human herpesvirus identified as an oncogenic agent, with approximately 95% of adults worldwide being latently infected. EBV infection is associated with multiple diseases, including nasopharyngeal carcinoma, Hodgkin’s lymphoma, infectious mononucleosis, and multiple sclerosis. Given significant EBV-associated disease burden, developing effective vaccines against EBV remains a priority. In this review, we first presented the current understanding of EBV biology and pathogenesis, focusing on its biological structure and immune evasion mechanisms, and discussed key viral antigens—including gp350, gp42, gH/gL, and latency proteins—as potential targets for EBV vaccine development. We also summarized recent advances in various EBV vaccine platforms, including subunit, viral vector-based, nanoparticle-based, and mRNA vaccines, and discussed the related preclinical and clinical evidence, although no effective EBV vaccine has been approved for clinical use yet. In summary, this review provides an overview of the current landscape in EBV vaccine research, and sheds new light on developing new therapeutic approaches against EBV-associated diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 4, HumanEpstein-Barr Virus InfectionsVaccine DevelopmentViral VaccinesHerpesvirus VaccinesHumansAnimalsAntigens, ViralViral Proteins

Stichwörter der Autor:innen

Epstein–Barr virusglycoproteinvaccine

Substanzen

Viral VaccinesAntigens, ViralHerpesvirus VaccinesViral Proteins

Autor:innen und Institutionen

  • School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
  • Guangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen 518172, China.

Förderung

  • Shenzhen Science and Technology Program (Conglei Li)
  • Guangdong Basic and Applied Basic Research Foundation (Conglei Li)
  • Shenzhen Medical Research Fund (Conglei Li)
  • the National Science Fund of China (Conglei Li)
  • National Science Fund of China
  • Guangdong Basic Research Center of Excellence for Aggregate Science, School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen, Guangdon…

Zitieren

APA

Dai, Y., Zhang, B., Yang, L., Tao, S., Yu, Y., & Li, C. (2025). Recent Progress in the Vaccine Development Against Epstein–Barr Virus. Viruses, 17(7), 936. https://doi.org/10.3390/v17070936

Vancouver

Dai Y, Zhang B, Yang L, Tao S, Yu Y, Li C. Recent Progress in the Vaccine Development Against Epstein–Barr Virus. Viruses. 2025;17(7):936. doi:10.3390/v17070936

BibTeX
@article{Dai2025,
  author = {Dai, Yihao and Zhang, Botian and Yang, Luming and Tao, Shuo and Yu, Yijing and Li, Conglei},
  title = {Recent Progress in the Vaccine Development Against Epstein–Barr Virus},
  journal = {Viruses},
  year = {2025},
  volume = {17},
  number = {7},
  pages = {936},
  doi = {10.3390/v17070936}
}
Kostenlos starten →